Century Therapeutics, Inc. (IPSC) - Dilution Analysis

10-Q filing | 193.5M shares outstanding

10-K filing | 179.7M shares outstanding

8-K filing: Century Therapeutics, Inc. entered into a securities purchase agreement to issue and sell 92,030,595 shares of common stock and pre-funded warrants to purchase 25,360,704 shares of common stock, along with warrants to purchase 58,695,648 shares of common stock, in a private placement expected to close on or about January 9, 2026, with gross proceeds of approximately $135.0 million. ($135.0M proceeds)

S-3/A filing: This is an S-3/A filing for Century Therapeutics, Inc., filed on 2026-01-05, which is a pre-effective Amendment No. 1 to its Registration Statement on Form S-3 (333- 288616) as an exhibit-only filing solely to file an updated auditor consent as Exhibit 23.1.

10-Q filing | 86.5M shares outstanding

S-3 filing: Century Therapeutics, Inc. files an S-3 registration statement to offer and sell up to $200,000,000 in the aggregate of common stock, preferred stock, debt securities, warrants, units, and subscription rights from time to time.

10-Q filing | 86.1M shares outstanding

10-K filing | 78.6M shares outstanding

10-Q filing | 84.7M shares outstanding

10-Q filing | 82.1M shares outstanding

S-3 filing: Century Therapeutics, Inc. is offering 7,868,666 shares of common stock for resale by selling stockholders.

S-3 filing: This S-3 filing registers 15,873,011 shares of common stock for resale by selling stockholders, which were previously issued in a private placement, with the company not receiving any proceeds from the sale.

10-Q filing | 62.3M shares outstanding

8-K filing: Century Therapeutics, Inc. entered into a securities purchase agreement to sell 15,873,011 shares of common stock at $3.78 per share and completed a merger with Clade Therapeutics, issuing 4,535,333 shares of Century's common stock as part of the upfront consideration. ($60.0M proceeds)

10-K filing | 57.8M shares outstanding

10-Q filing | 59.4M shares outstanding

10-Q filing | 59.3M shares outstanding

10-Q filing | 58.6M shares outstanding

10-K filing | 57.8M shares outstanding

10-Q filing | 58.0M shares outstanding

10-Q filing | 57.7M shares outstanding

S-3 filing: The company intends to offer shares of its common stock from time to time through its sales agent, Cowen, for an aggregate offering price of up to $150,000,000, primarily for general corporate purposes, including funding research, clinical development, process development and manufacturing of its product candidates, working capital and capital expenditures.

10-Q filing | 57.1M shares outstanding

10-K filing | 7.5M shares outstanding

8-K filing: Century Therapeutics, Inc. sold 2,160,760 shares of its common stock to Bristol-Myers Squibb Company at a price of $23.14 per share, for an aggregate purchase price of $50 million, with the closing expected on January 12, 2022. ($50.0M proceeds)

10-Q filing | 54.5M shares outstanding

10-Q filing | 54.4M shares outstanding

S-1/A filing: This is the initial public offering of shares of common stock of Century Therapeutics, Inc.

S-1/A filing: This is an S-1/A filing for the initial public offering of common stock of Century Therapeutics, Inc., offering 10,550,000 shares with an estimated price range of $18.00 to $20.00 per share.

S-1 filing: This is an S-1 filing for the initial public offering of common stock of Century Therapeutics, Inc.